Aurinia CLO granted 115,541 performance stock units

Robertson Stephen P. reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Robertson Stephen P. reported acquisition or exercise transactions in this Form 4 filing.

Aurinia Pharmaceuticals Inc. reported that its Chief Legal Officer, Stephen P. Robertson, received an equity compensation award in the form of 115,541 performance stock units. These units were granted at no cash cost per unit and increase his direct holdings to 621,402 common shares or share-based units reported in this filing.

The footnote explains that each performance stock unit represents a contingent right to receive one common share of Aurinia. The 115,541 units vest in two tranches on the third and fifth anniversaries of the grant date, only if Aurinia’s common shares reach target prices that represent significant increases from the grant-date share price before each vesting date.

Insights

Equity compensation analyst

Chief Legal Officer received performance-based equity, a routine compensation award.

Aurinia Pharmaceuticals granted Chief Legal Officer Stephen P. Robertson 115,541 performance stock units at a grant price of $0.00 per unit. This is classified as a grant or award acquisition, not an open-market purchase, and is typical for senior executive compensation.

The award vests in two tranches at the three- and five-year anniversaries of grant, but only if the company’s share price achieves specified target prices that are significantly higher than the grant-date price. Following this grant, Robertson’s total reported direct holdings are 621,402 common shares or share-based units.

Insider Trade Summary

Grant/Award: 115,541 shares

Grant/Award 1 txn

Insider Robertson Stephen P.

Role Chief Legal Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	115,541	$0.00	$0.00

Holdings After Transaction: Common Stock — 621,402 shares (Direct)

Footnotes (1)

1. F1. Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 115,541 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.

Key Figures

Performance stock units granted: 115,541 units Grant price per unit: $0.00 per unit Holdings after transaction: 621,402 shares +1 more

4 metrics

Performance stock units granted 115,541 units Grant to Chief Legal Officer Stephen P. Robertson

Grant price per unit $0.00 per unit Performance stock unit award

Holdings after transaction 621,402 shares Total directly reported common shares or share-based units

Vesting schedule 3-year and 5-year tranches PSUs vest at third and fifth anniversaries if price targets are met

Key Terms

performance stock unit ("PSU"), contingent right, vest, target prices

4 terms

performance stock unit ("PSU") financial

"Each performance stock unit ("PSU") represents a contingent right to receive one common share"

contingent right financial

"represents a contingent right to receive one common share of the Issuer"

vest financial

"115,541 PSUs vest in two tranches at the three and five year anniversary date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

target prices financial

"if the Issuer's common shares achieve target prices that represent significant increases"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Aurinia Pharmaceuticals (AUPH) report in this Form 4 for Stephen P. Robertson?

Aurinia reported that Chief Legal Officer Stephen P. Robertson received a grant of 115,541 performance stock units. These units were awarded at no cash cost and increase his directly reported holdings to 621,402 common shares or share-based units, according to the Form 4.

How many performance stock units did AUPH’s Chief Legal Officer receive?

Stephen P. Robertson received 115,541 performance stock units. Each unit represents a contingent right to receive one Aurinia common share, subject to vesting conditions tied to future share-price targets and specific vesting dates described in the Form 4 footnote.

What are performance stock units (PSUs) in Aurinia Pharmaceuticals’ Form 4?

In this filing, each performance stock unit is a contingent right to receive one Aurinia common share. The 115,541 PSUs vest only if the company’s common shares reach target prices that significantly exceed the grant-date share price before the scheduled vesting anniversaries.

When do the granted AUPH performance stock units vest for Stephen P. Robertson?

The 115,541 performance stock units vest in two tranches at the three- and five-year anniversaries of the grant date. Vesting occurs only if Aurinia’s common shares achieve specified target prices that represent significant increases from the share price on the grant date.

Did Stephen P. Robertson buy or sell AUPH shares on the open market?

No open-market buy or sell was reported. The Form 4 shows a grant classified as a grant, award, or other acquisition of 115,541 performance stock units, awarded at a price of $0.00 per unit as part of compensation rather than a market transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 05:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Robertson Stephen P.

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON T5L 4S6

(City) (State) (Zip)

ALBERTA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A		115,541(1)	A	$0	621,402	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each performance stock unit ("PSU") represents a contingent right to receive one common share of the Issuer. 115,541 PSUs vest in two tranches at the three and five year anniversary date of grant if the Issuer's common shares achieve target prices that represent significant increases from the share price on date of grant before the respective vesting date.

Remarks:

	/s/ Stephen P. Robertson	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)